Last reviewed · How we verify
BIAsp 30
BIAsp 30, marketed by Novo Nordisk A/S, is a well-established diabetes treatment with a strong presence in the market. The drug's key strength lies in its unique mechanism of action, which differentiates it from competitors. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | BIAsp 30 |
|---|---|
| Also known as | NovoMix®, Novomix 30 |
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes
- Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Failing on OADs (PHASE4)
- Bioequivalence Study of INS062 and Pharmacokinetics and Pharmacokinetics Study of Single Injection of HR20014 in Healthy Subjects (PHASE1)
- Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy (PHASE4)
- Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids (PHASE4)
- A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria
- A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects (NA)
- Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIAsp 30 CI brief — competitive landscape report
- BIAsp 30 updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI